Copy to clipboard 
Enovis announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. He will also join the Enovis Board of Directors.
Mr. McDonald will succeed Matt Trerotola, who previously announced his intention to retire as CEO.
Enovis also reiterated its expectations for first-quarter revenues to be in the range of $555 million to $563 million.
Mr. McDonald joins Enovis with more than 35 years of experience in the medical device industry. Most recently, he served as CEO of LivaNova. Earlier in his career, he was a Group Executive and Corporate Vice President leading a $1.5 billion group of dental consumables companies at Danaher, where Mr. Trerotola also held a past management role. Additionally, McDonald previously led Zimmer’s spine division and global marketing for J&J’s Ethicon business unit.
“I am honored to join the Enovis team at this exciting time in the Company’s history and to have the opportunity to lead the Company into its next phase of growth,” says Mr. McDonald. “I share the Company’s vision of developing innovative technologies to improve patient outcomes and I look forward to building upon Enovis’ strong foundation and delivering exceptional value for all of our stakeholders.”
Mr. Trerotola said, “Damien has the experience, track record, and cultural fit to be a fantastic next leader of Enovis. I am grateful for the opportunity to lead Colfax and Enovis for the past decade and look forward to a smooth transition that continues to build on the Company’s great operational and strategic momentum.”
Source: Enovis
Enovis announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. He will also join the Enovis Board of Directors.
Mr. McDonald will succeed Matt Trerotola, who previously announced his intention to retire as CEO.
Enovis also reiterated its expectations for first-quarter revenues to be in the range...
Enovis announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. He will also join the Enovis Board of Directors.
Mr. McDonald will succeed Matt Trerotola, who previously announced his intention to retire as CEO.
Enovis also reiterated its expectations for first-quarter revenues to be in the range of $555 million to $563 million.
Mr. McDonald joins Enovis with more than 35 years of experience in the medical device industry. Most recently, he served as CEO of LivaNova. Earlier in his career, he was a Group Executive and Corporate Vice President leading a $1.5 billion group of dental consumables companies at Danaher, where Mr. Trerotola also held a past management role. Additionally, McDonald previously led Zimmer’s spine division and global marketing for J&J’s Ethicon business unit.
“I am honored to join the Enovis team at this exciting time in the Company’s history and to have the opportunity to lead the Company into its next phase of growth,” says Mr. McDonald. “I share the Company’s vision of developing innovative technologies to improve patient outcomes and I look forward to building upon Enovis’ strong foundation and delivering exceptional value for all of our stakeholders.”
Mr. Trerotola said, “Damien has the experience, track record, and cultural fit to be a fantastic next leader of Enovis. I am grateful for the opportunity to lead Colfax and Enovis for the past decade and look forward to a smooth transition that continues to build on the Company’s great operational and strategic momentum.”
Source: Enovis
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
